Jana Uhrova

Jana Uhrova

Auto-generated profile, based on publicly available information

Jana Uhrova

Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Affective Disorders
Verified
Journal Article
Closed access
PBPetr Bob
Petr Bob
JRJiri Raboch
Jiri Raboch
MMMichael Maes
Michael Maes
MSMarek Susta
Marek Susta
JPJosef Pavlat
Josef Pavlat
TZTomas Zima
Tomas Zima

1 January 2012 in Circulation Journal
Verified
Journal Article
Closed access
TKTomas Kovarnik
Tomas Kovarnik
GMGary S. Mintz
Gary S. Mintz
HSHana Skalicka
Hana Skalicka
AKAles Kral
Ales Kral
JHJan Horak
Jan Horak
ALAleš Linhart
Aleš Linhart
There is no study focusing on changes in coronary atherosclerosis during dual lipid-lowering therapy with statin and ezetimibe. Eighty-nine patients with stable angina randomized in a 1:1 ratio to Group A (aggressive therapy: atorvastatin 80mg, ezetimibe 10mg) and Group S (standard therapy) were analyzed. Treatment period was 12 months. Coronary arteries were examined by intravascular ultrasound and virtual histology. We found a decrease in the percent atheroma volume (PAV) (-0.4%) in Group A compared with an increase (+1.4%) in Group S (P=0.014) and this was accompanied by an increased frequency of combined atherosclerosis regression (increased lumen volume+decreased PAV) in group A (40.5%) compared with group S (14.9%) (P=0.007). The target low-density lipoprotein cholesterol level <2mmol/L, presence of at least 4 of 5 atherosclerotic risk factors, and decreased level of vascular cellular adhesive molecule were independent predictors of plaque regression. There were no significant differences in plaque composition between the 2 groups over the study duration. However, during analysis of the 2 groups together, fibrous and fibro-fatty tissues decreased and dense calcification and necrotic core increased during follow-up. Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition. The continuous shift in plaque from fibro and fibro-fatty to necrotic with calcification was present in both groups.

14 April 2011 in Cells Tissues Organs
Verified
Journal Article
Closed access
PDF file
BDBarbora Dvorankova
Barbora Dvorankova
PSPavol Szabo
Pavol Szabo
Lukas LacinaLukas Lacina
Lukas Lacina
Peter GalPeter Gal
Peter Gal
JUJana Uhrova
Jana Uhrova
Karel SmetanaKarel Smetana
Karel Smetana
Members of the galectin family of endogenous lectins are potent adhesion/growth-regulatory effectors. Their multifunctionality opens possibilities for their use in bioapplications. We studied whether human galectins induce the conversion of human dermal fibroblasts into myofibroblasts (MFBs) and the production of a bioactive extracellular matrix scaffold is suitable for cell culture. Testing a panel of galectins of all three subgroups, including natural and engineered variants, we detected activity for the proto-type galectin-1 and galectin-7, the chimera-type galectin-3 and the tandem-repeat-type galectin-4. The activity of galectin-1 required the integrity of the carbohydrate recognition domain. It was independent of the presence of TGF-β1, but it yielded an additive effect. The resulting MFBs, relevant, for example, for tumor progression, generated a matrix scaffold rich in fibronectin and galectin-1 that supported keratinocyte culture without feeder cells. Of note, keratinocytes cultured on this substratum presented a stem-like cell phenotype with small size and keratin-19 expression. In vivo in rats, galectin-1 had a positive effect on skin wound closure 21 days after surgery. In conclusion, we describe the differential potential of certain human galectins to induce the conversion of dermal fibroblasts into MFBs and the generation of a bioactive cell culture substratum.

1 January 2007 in Tumor Biology
Verified
Journal Article
Closed access
PSPetr Stern
Petr Stern
VBVladimir Bartos
Vladimir Bartos
JUJana Uhrova
Jana Uhrova
DBDrahomira Bezdickova
Drahomira Bezdickova
ZVZdislava Vanickova
Zdislava Vanickova
TZTomas Zima
Tomas Zima

1 October 2009 in Kidney and Blood Pressure Research
Verified
Journal Article
Closed access
MPM. Peiskerová
M. Peiskerová
MKMarta Kalousova
Marta Kalousova
MKM. Kratochvílová
M. Kratochvílová
SDS. Dusilová-Sulková
S. Dusilová-Sulková
JUJ. Uhrová
J. Uhrová
VTV. Tesař
V. Tesař
Background: High cardiovascular risk in patients with chronic kidney disease (CKD) may be related to mineral disorder and microinflammation. Fibroblast growth factor 23 (FGF-23) is a phosphatonin and inhibitor of calcitriol synthesis, which is associated with poor prognosis in CKD patients starting dialysis. Matrix-metalloproteinases (MMP-2, MMP-9) contribute to myocardial remodeling and arterial calcification. FGF-23 and MMPs levels are altered in CKD, however, little is known about their association and relation to cardiovascular (CV) disease. Methods: Standard laboratory parameters, plasma levels of MMP-2, MMP-9, FGF-23, PAPP-A and CV disease history were assessed in 80 patients with CKD 1–5 and 44 healthy control subjects. Results: FGF-23 and MMP-2 (assessed by ELISA) were higher in CKD patients compared to controls. FGF-23 increased from CKD 3, whereas MMP-2 increased only in CKD 5. FGF-23 was positively associated with MMP-2, adjusted to age, eGFR, phosphatemia, calcitriol and parathormone. FGF-23 independently correlated with parathormone and inversely with calcitriol, whereas MMP-2 was related to phosphatemia. FGF-23 was higher in subjects with a history of CV disease compared to those free of such history (559.0 vs.184.0 RU/ml), adjusted to age and eGFR. Conclusion: Our data suggest a possible relationship between FGF-23, MMP-2 and CV disease in CKD. Potential causality of this association remains to be elucidated.

7 January 2001 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PSPetr Stern
Petr Stern
BFBedrich Friedecky
Bedrich Friedecky
VBVladimir Bartos
Vladimir Bartos
DBDrahomira Bezdickova
Drahomira Bezdickova
JVJaroslava Vavrova
Jaroslava Vavrova
VPVladimir Palicka
Vladimir Palicka
We compared six routinely employed immunoassay kits: Architect i2000 and AxSYM, Abbott Laboratories; Elecsys 2010, Roche Diagnostics; ELSA, CIS-BioInternational; Immulite 1, Diagnostic Products Corporation; and IRMA-mat, Byk-Sangtec Diagnostica. Using all analytical systems, we measured identical groups of clinical samples completed with selected control samples. The repeatability of measurements (coefficient of variation) ranged from 2.1% (Elecsys 2010) to 6.7% (ELSA). The parameters of Passing-Bablok regression show significant systematic differences among analytical systems. Data from a Bland-Altman diagram suggest that these differences project onto other, still more significant individual differences among individual samples. Though the cut-off values differ between various systems, no similar clinical efficacy appears to be attained. The behavior of individual systems is quite different for identical control materials and does not necessarily duplicate the calibration for biological samples. The results of determining CA 19-9 cannot be extrapolated from one analytical technique to another, even in cases where the same monoclonal antibody is used. Standardization of CA 19-9 measurement systems is necessary to allow use of the results for the purposes of evidence-based medicine.